Why vital chemotherapy drugs in short supply in India
India is facing a critical nationwide shortage of key chemotherapy drugs, cisplatin and carboplatin, due to soaring global platinum raw material costs, West Asia shipping disruptions restricting raw material imports, and domestic price caps. While government hospitals have managed to stabilize supplies, private hospitals are struggling, leading to treatment interruptions for cancer patients. In response, the government, through the NPPA, temporarily raised the ceiling prices of these drugs by 50% to restart domestic manufacturing, highlighting vulnerabilities in India's drug supply chains and pricing framework.
Key Points
- India is experiencing a critical shortage of cisplatin and carboplatin, vital chemotherapy drugs, due to multiple factors.
- The primary causes include a more than doubling of platinum raw material prices, shipping constraints via West Asia, and unviable domestic price caps.
- The shortage has led to treatment interruptions and delays for cancer patients, particularly in private hospitals, while government hospitals have managed to stabilize supplies.
- The National Pharmaceutical Pricing Authority (NPPA) intervened by raising the ceiling prices of cisplatin and carboplatin by approximately 50% to incentivize domestic manufacturing.
- This situation underscores the need for a long-term strategy to ensure raw material security, resilient logistics, and balanced pricing policies in India's drug supply chains.
Exam Facts
- Drugs in shortage: Cisplatin and Carboplatin.
- NPPA raised price cap by ~50% on June 12.
- Cisplatin price cap raised from ₹7.26 to ₹10.89 per ml.
- Carboplatin price cap raised from ₹60.49 to ₹90.74 per ml.
Read it. Retain it. Recall it.
Get spaced-repetition flashcards, daily quizzes and offline access — free on Android.